Selective mPGES-1 Inhibitors for Anti-Inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mPGES-1 inhibitors are not sufficiently potent and are associated with adverse side effects, necessitating the development of novel compounds that can effectively inhibit microsomal prostaglandin E synthase-1 to treat inflammatory disorders without the gastrointestinal issues seen with existing anti-inflammatory drugs.
Innovation Solution
The development of specific compounds, including those represented by various chemical formulas, which act as potent inhibitors of mPGES-1, potentially offering improved anti-inflammatory effects with reduced side effects by selectively blocking the production of PGE2 without affecting other prostaglandins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX inhibitors are used to prevent prostaglandin production, then anti-inflammatory effect is improved, but gastrointestinal side effects worsen
Solution Approach 1:
The invention segments the prostaglandin synthesis pathway by targeting the terminal step (mPGES-1) rather than the upstream COX enzymes. This selective inhibition of mPGES-1 allows blocking of inflammatory PGE2 production while preserving other prostaglandins like PGI2 that protect the gastrointestinal tract, thereby resolving the contradiction between anti-inflammatory efficacy and gastrointestinal safety
Solution Approach 2:
The patent applies local quality by creating an inhibitor with selective action on mPGES-1 enzyme specifically involved in inflammatory pathways. The compound exhibits preferential binding to mPGES-1 over other prostaglandin synthases, enabling localized suppression of inflammatory response without broadly affecting protective prostaglandin pathways in the gastrointestinal system
2Reliability
If existing mPGES-1 inhibitors are used, then PGE2 production is blocked, but inhibition potency is insufficient
Solution Approach 1:
The invention employs parameter changes by systematically modifying chemical structure parameters of the core heterocyclic scaffold (barbituric acid, thiobarbituric acid, oxindole, isatin). By varying substituents at specific positions (R1-R6 groups) and adjusting molecular properties, the patent achieves significantly enhanced binding affinity and inhibition potency against mPGES-1, transforming weak inhibitors into potent therapeutic agents
Solution Approach 2:
The patent creates composite molecular structures by combining heterocyclic core scaffolds with various functional groups and substituents. These composite structures integrate multiple pharmacophoric elements that work synergistically to achieve high potency: the core heterocycle provides mPGES-1 binding while attached groups enhance affinity and selectivity, resulting in compounds with superior inhibition capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate significant inhibition of mPGES-1 activity, providing effective anti-inflammatory treatment for conditions like arthritis, fever, pain, and stroke with potentially fewer side effects compared to existing NSAIDs.
Implementation Method 1
microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors
Data Source
AI summary
Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.